Yulia Slavina

CVRx publishes BENEFIT-HF trial design in peer-reviewed journal

CVRx publishes BENEFIT-HF trial design in peer-reviewed journal
CVRx publishes BENEFIT-HF design

CVRx has announced the publication of the BENEFIT-HF trial design paper in the Journal of Cardiac Failure.

The article presents the methodology for a prospective, randomized, controlled, multicenter clinical study examining heart failure interventions. The trial is backed by CMS Category B IDE coverage, a pathway designed to support innovative medical devices in clinical evaluation. The newly published paper will serve as a reference for stakeholders and researchers monitoring the progress of next-generation heart failure therapies.

CVRx recently celebrated its 25th Barostim implant milestone at UNC Medical Center Chapel Hill. The company also announced a national agreement with Humana to cover Barostim therapy through Medicare Advantage plans. These developments come as CVRx advances clinical research in heart failure interventions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.